Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study

View ORCID ProfileSarah E. Daugherty, Yinglong Guo, Kevin Heath, Micah C. Dasmariñas, Karol Giuseppe Jubilo, Jirapat Samranvedhya, Marc Lipsitch, Ken Cohen
doi: https://doi.org/10.1101/2021.03.12.21253448
Sarah E. Daugherty
1OptumLabs at UnitedHealth Group, 5995 Opus Parkway, Minneapolis, MN 55343
Roles: Senior Researcher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah E. Daugherty
  • For correspondence: SarahDaugherty@uhg.com
Yinglong Guo
1OptumLabs at UnitedHealth Group, 5995 Opus Parkway, Minneapolis, MN 55343
Roles: Director
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Heath
2OptumCare, KS999-1000PO Box 9472, Minneapolis, MN 55440-9472
3Harvard T.H Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115
Roles: National Medical Director for Clinical Intelligence
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Micah C. Dasmariñas
1OptumLabs at UnitedHealth Group, 5995 Opus Parkway, Minneapolis, MN 55343
Roles: Data Scientist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karol Giuseppe Jubilo
1OptumLabs at UnitedHealth Group, 5995 Opus Parkway, Minneapolis, MN 55343
Roles: Data Scientist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jirapat Samranvedhya
1OptumLabs at UnitedHealth Group, 5995 Opus Parkway, Minneapolis, MN 55343
Roles: Principal Data Scientist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Lipsitch
3Harvard T.H Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115
Roles: Professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Cohen
2OptumCare, KS999-1000PO Box 9472, Minneapolis, MN 55440-9472
4OptumLabs at UnitedHealth Group, 1707 Cole Blvd., Suite 100, Golden, CO 80401
Roles: Executive Director Translational Research
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective Clinical sequelae have not been well characterized during the post-acute phase of SARS-CoV-2 among adults 18 to 65 years old, and this study sought to fill that gap by evaluating excess risk and relative hazards for developing incident clinical sequelae during the post-acute phase.

Design Retrospective cohort study including three propensity-matched groups.

Setting This study merged three data sources from a large United States health plan: a large national administrative claims database, an outpatient lab testing database, and an inpatient hospital admissions database.

Participants Individuals 18 to 65 years old with continuous health plan enrollment from January 2019 to date of SARS-CoV-2 diagnosis. Three comparator groups were identified and propensity-score matched to individuals infected with SARS-CoV-2: a 2020 comparator group, a historical 2019 comparator group and a historical comparator group with viral lower respiratory tract illness (vLRTI).

Main outcome measures Over 50 clinical sequelae during the post-acute phase (index date + 21 days) were ascertained using ICD-10 codes. Excess risk due to SARS-CoV-2 during the 4 months following the acute phase of illness and hazard ratios with 95% Bonferroni-corrected confidence intervals were calculated.

Results This study found 14% of adults ≤65 years of age who were infected with SARS-CoV-2 (n=193113) had at least one new clinical sequelae that required medical attention during the post-acute phase of illness. When considering risk for specific sequelae attributable to SARS-Cov-2 infection during the post-acute phase, clinical outcomes including chronic respiratory failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia (memory difficulty), diabetes, liver test abnormalities, myocarditis, anxiety and fatigue were significantly elevated compared to the three propensity-matched comparator groups (2020, 2019, vLRTI). Significant risk differences due to SARS-CoV-2 infection ranged from 0.02 to 2.26 per 100 people and hazard ratios ranged from 1.24 to 25.65 when compared to the 2020 comparator group.

Conclusions Our results confirm excess risk for developing clinical sequelae due to SARS-CoV-2 during the post-acute phase, including specific types of sequelae less commonly seen among other viral illnesses. Although individuals who were older, had pre-existing conditions, and were hospitalized due to COVID-19 were at greatest excess risk, younger adults (≤50 years), adults who did not have pre-existing conditions or adults who were not hospitalized due to COVID-19 were still at elevated risk for developing new clinical sequelae. The elevated risk for incident sequelae during the post-acute phase is relevant for healthcare planning.

What is already known on this topic Small observational studies and case reports of hospitalized patients have shown some COVID-19 survivors suffer from short- and long-term sequelae. Few studies have characterized the excess risk of clinical sequelae attributable to SARS-CoV-2 during the post-acute phase among adults ≤65 years of age in a large generalizable sample.

What this study adds This study found 14% of individuals ≤65 years of age who were infected with SARS-CoV-2 (n=193113) had a diagnosis of at least one new sequelae that required medical attention during the post-acute phase of illness. Elevated risk for specific clinical sequelae during the post-acute phase of illness was noted across a range of organ systems including cardiovascular, neurologic, kidney, respiratory, and mental health complications. The risk for incident sequelae increases with age, pre-existing conditions, and hospitalization for COVID-19; however, even among adults ≤ 50 years of age and individuals without pre-existing conditions or hospitalization due to COVID-19, risk for some clinical sequelae is still elevated. These results indicate where additional diagnostic follow-up, rehabilitation, and symptom management may be warranted among younger adults with milder infection.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and SED, YG, KH, JS, MD, KGJ declare that they have had no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted. KC declares consulting from Pfizer. ML declares honoraria/consulting from Merck, Sanofi-Pasteur, Bristol Myers-Squibb, and Antigen Discovery; research funding (institutional) from Pfizer, and an unpaid scientific advice to Janssen, Astra-Zeneca, One Day Sooner, and Covaxx (United Biomedical).

Funding Statement

The study was funded by OptumLabs, the research and development arm of UnitedHealth Group, and the authors Drs. Daugherty, Cohen, Heath, and Mr. Guo, Ms. Dasmarinas, Mr. Jubilo, and Mr. Samranvedhya are full-time employees at UnitedHealth Group.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research was determined to be exempt from human research regulations by the UnitedHealth Group Office of Human Research Affairs (Action ID: 2020-0076-01).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data are proprietary and are not available for public use but, under certain conditions, may be made available to editors and their approved auditors under a data use agreement to confirm the findings of the current study.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study
Sarah E. Daugherty, Yinglong Guo, Kevin Heath, Micah C. Dasmariñas, Karol Giuseppe Jubilo, Jirapat Samranvedhya, Marc Lipsitch, Ken Cohen
medRxiv 2021.03.12.21253448; doi: https://doi.org/10.1101/2021.03.12.21253448
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study
Sarah E. Daugherty, Yinglong Guo, Kevin Heath, Micah C. Dasmariñas, Karol Giuseppe Jubilo, Jirapat Samranvedhya, Marc Lipsitch, Ken Cohen
medRxiv 2021.03.12.21253448; doi: https://doi.org/10.1101/2021.03.12.21253448

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (419)
  • Anesthesia (97)
  • Cardiovascular Medicine (894)
  • Dentistry and Oral Medicine (166)
  • Dermatology (101)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
  • Epidemiology (8744)
  • Forensic Medicine (4)
  • Gastroenterology (403)
  • Genetic and Genomic Medicine (1844)
  • Geriatric Medicine (175)
  • Health Economics (386)
  • Health Informatics (1281)
  • Health Policy (642)
  • Health Systems and Quality Improvement (488)
  • Hematology (206)
  • HIV/AIDS (387)
  • Infectious Diseases (except HIV/AIDS) (10520)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (216)
  • Neurology (1744)
  • Nursing (100)
  • Nutrition (264)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (457)
  • Oncology (959)
  • Ophthalmology (279)
  • Orthopedics (107)
  • Otolaryngology (174)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (262)
  • Pediatrics (553)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1836)
  • Public and Global Health (3962)
  • Radiology and Imaging (649)
  • Rehabilitation Medicine and Physical Therapy (340)
  • Respiratory Medicine (532)
  • Rheumatology (214)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (165)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (105)
  • Urology (78)